Scientists are entering a new era for studying psychedelics. Research in the 1950s and '60s was cut short in the '70s due to media coverage and regulations. In 2000, Johns Hopkins gained regulatory approval to restart research with psychedelics, publishing a landmark study in 2006 on psilocybin's safety and positive effects. Their work explores therapeutic effects for conditions like addiction, existential distress, depression, and more. Studying healthy volunteers has enhanced understanding of psilocybin's effects and neurophysiological mechanisms. The Psilouette's mission is to advance psychedelic research and therapy, conducting ethical clinical trials, elucidating mechanisms, and providing evidence-based education for innovative therapeutic approaches.